Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients

P. L. Zinzani, M. Tani, S. Fanti, L. Alinari, G. Musuraca, E. Marchi, V. Stefoni, P. Castellucci, M. Fina, M. Farshad, S. Pileri, M. Baccarani

Research output: Contribution to journalArticlepeer-review

Abstract

Background: It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients. Patients and methods: Between June 2003-September 2004, in our institute, 40 newly-diagnosed patients with advanced stage HD were consecutively treated with ABVD chemotherapy for six cycles. All these patients underwent staging/restaging: computed tomography (CT) and positron emission tomography (PET) at time 0, PET after two cycles, CT and PET after four and six cycles. Results: After two cycles (PET-2), the PET was negative in 28/40 (70%), positive in 8/40 (20%), and minimal residual uptake (MRU) was present in the remaining four (10%) patients. After treatment, among eight patients who were PET-2+, seven showed refractory disease and one had relapse after 3 months. All four patients with MRU at the PET-2 became PET- during the further four cycles and, after treatment, three were in complete response (CR) and one relapsed after 5 months. All 28 PET negative patients at the PET-2 remained PET negative and all of them were in CR after treatment. Conclusions: The PET use for early (after two cycles) response assessment in HD patients is a significant step forward and has the potential to help physicians make crucial decisions about further treatment.

Original languageEnglish
Pages (from-to)1296-1300
Number of pages5
JournalAnnals of Oncology
Volume17
Issue number8
DOIs
Publication statusPublished - Aug 2006

Keywords

  • Chemotherapy
  • Early response
  • HD
  • PET

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients'. Together they form a unique fingerprint.

Cite this